Insider Trading activities of Dexcom Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Dexcom Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Dexcom Inc since year 2005. Table 2 shows the detailed insider transactions of Dexcom Inc since 2005. The reporting company's ticker symbol is DXCM. The reporting company's CIK number is 1093557.
The total value of stock buying since 2005 is $6,467,394.
The total value of stock sales since 2005 is $598,341,434.
The total value of stock option exercises since 2005 is $35,554,192.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Dexcom Inc (DXCM).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2018-10 0 $0 19,061 $2,408,829 11,161 $51,117
2018-09 0 $0 136,538 $19,633,675 26,161 $139,917
2018-08 0 $0 79,067 $10,060,102 31,738 $144,845
2018-07 0 $0 34,914 $3,501,714 0 $0
2018-06 0 $0 91,774 $8,697,276 0 $0
2018-05 0 $0 104,458 $8,971,469 106,451 $720,008
2018-04 0 $0 12,581 $919,060 0 $0
2018-03 0 $0 12,581 $831,763 0 $0
2018-02 0 $0 11,638 $651,352 0 $0
2018-01 0 $0 11,635 $657,973 0 $0
2017-12 0 $0 10,880 $643,989 0 $0
2017-11 35,000 $1,746,350 28,525 $1,615,640 0 $0
2017-10 0 $0 1,635 $73,274 0 $0
2017-09 0 $0 12,329 $865,783 0 $0
2017-08 0 $0 14,866 $1,072,656 0 $0
2017-07 0 $0 10,650 $760,867 0 $0
2017-06 0 $0 13,837 $998,052 0 $0
2017-05 0 $0 16,481 $1,137,953 33,649 $237,574
2017-04 0 $0 32,832 $2,469,199 10,000 $87,899
2017-03 0 $0 95,976 $7,455,791 52,390 $404,789
2017-02 0 $0 42,615 $3,412,745 34,627 $326,393
2017-01 0 $0 84,031 $6,496,372 77,837 $662,044
2016-12 0 $0 15,624 $1,002,531 10,000 $76,100
2016-11 0 $0 16,899 $1,161,177 0 $0
2016-10 0 $0 47,510 $3,927,959 11,000 $83,930
2016-09 0 $0 125,242 $11,708,480 16,999 $107,506
2016-08 0 $0 328,552 $29,928,996 87,004 $696,904
2016-07 0 $0 93,885 $7,818,709 42,000 $276,060
2016-06 0 $0 368,568 $27,559,316 180,000 $620,200
2016-05 0 $0 99,002 $6,242,405 20,000 $196,000
2016-04 0 $0 63,971 $4,468,386 20,000 $155,800
2016-03 0 $0 38,696 $2,392,252 0 $0
2016-02 0 $0 3,560 $222,500 0 $0
2016-01 0 $0 33,295 $2,530,624 0 $0
2015-12 0 $0 85,119 $7,185,230 59,000 $407,960
2015-11 0 $0 256,142 $21,784,051 211,001 $1,638,808
2015-10 0 $0 50,420 $4,058,170 20,000 $196,000
2015-09 0 $0 247,099 $23,468,733 190,000 $1,283,223
2015-08 0 $0 145,601 $13,755,602 48,392 $390,485
2015-07 0 $0 176,661 $14,537,192 70,000 $705,930
2015-06 0 $0 175,552 $12,785,157 106,316 $744,932
2015-05 0 $0 371,989 $25,494,868 245,640 $1,461,838
2015-04 0 $0 166,448 $11,174,822 114,758 $1,498,909
2015-03 0 $0 186,159 $11,278,347 122,283 $1,445,564
2015-02 0 $0 79,253 $4,928,395 62,327 $569,108
2015-01 0 $0 119,210 $7,008,248 102,284 $967,219
2014-12 0 $0 159,079 $8,658,835 120,750 $833,925
2014-11 0 $0 375,636 $19,543,412 364,308 $3,158,163
2014-10 0 $0 100,400 $4,117,198 88,750 $639,845
2014-09 0 $0 100,518 $4,179,277 94,250 $600,715
2014-08 0 $0 473,494 $21,016,505 412,520 $3,031,108
2014-07 0 $0 130,500 $4,917,044 88,750 $602,365
2014-06 0 $0 164,500 $6,382,583 92,750 $621,665
2014-05 0 $0 134,957 $3,892,614 96,957 $513,161
2014-04 0 $0 129,884 $4,743,973 100,311 $600,512
2014-03 0 $0 448,985 $20,563,258 443,677 $3,670,026
2014-02 0 $0 280,925 $12,452,842 220,925 $1,592,280
2014-01 0 $0 93,000 $3,406,019 83,000 $578,470
2013-12 0 $0 210,130 $7,162,226 246,090 $1,456,943
2013-11 0 $0 197,322 $6,463,260 154,522 $690,993
2013-10 0 $0 9,000 $251,910 0 $0
2013-09 0 $0 9,000 $243,000 0 $0
2013-08 0 $0 9,000 $199,350 0 $0
2013-07 0 $0 9,000 $205,812 0 $0
2013-06 0 $0 46,361 $1,011,909 10,000 $24,000
2013-05 0 $0 60,272 $1,149,340 50,000 $123,950
2013-04 0 $0 9,000 $152,118 0 $0
2013-03 70,000 $1,085,000 58,070 $928,445 15,416 $7,708
2013-02 0 $0 75,000 $1,123,300 75,000 $239,250
2013-01 0 $0 9,000 $125,010 0 $0
2012-12 0 $0 68,347 $956,515 10,000 $31,900
2012-11 0 $0 5,000 $63,800 0 $0
2012-10 0 $0 5,000 $74,650 0 $0
2012-09 0 $0 24,000 $323,400 0 $0
2012-08 0 $0 36,249 $462,967 0 $0
2012-07 0 $0 5,000 $65,155 0 $0
2012-06 0 $0 17,077 $182,818 0 $0
2012-05 0 $0 19,198 $198,227 28,466 $14,233
2012-04 0 $0 5,000 $53,175 0 $0
2012-03 2,000 $20,710 5,000 $51,550 0 $0
2012-02 0 $0 5,000 $58,545 0 $0
2012-01 0 $0 5,000 $47,650 0 $0
2011-12 2,000 $16,068 0 $0 0 $0
2011-11 8,000 $56,760 0 $0 0 $0
2011-09 2,000 $24,708 0 $0 0 $0
2010-11 2,400 $28,449 0 $0 0 $0
2010-06 5,000 $50,250 0 $0 0 $0
2010-05 65,000 $690,779 0 $0 6,606 $46,109
2010-03 0 $0 10,000 $97,920 0 $0
2009-11 20,000 $143,768 0 $0 0 $0
2009-10 0 $0 0 $0 3,861 $24,440
2009-08 5,000 $34,225 0 $0 0 $0
2009-05 27,500 $103,660 0 $0 0 $0
2009-03 70,800 $285,075 0 $0 0 $0
2008-11 188,750 $336,279 0 $0 0 $0
2008-08 10,000 $66,700 0 $0 0 $0
2008-03 247,000 $1,205,523 0 $0 0 $0
2007-08 0 $0 3,296 $23,401 0 $0
2007-03 0 $0 4,000 $28,700 0 $0
2006-12 0 $0 17,363 $203,164 0 $0
2006-07 3,000 $33,600 0 $0 0 $0
2006-06 0 $0 0 $0 53,125 $21,250
2006-05 0 $0 3,482,500 $83,580,000 172,500 $56,500
2006-03 0 $0 40,648 $748,424 46,614 $23,307
2006-02 0 $0 0 $0 14,375 $4,312
2006-01 0 $0 0 $0 100,000 $50,000
2005-12 0 $0 4,000 $58,348 0 $0
2005-11 0 $0 2,333,900 $31,053,551 0 $0
2005-10 0 $0 611,000 $7,362,550 0 $0
2005-08 9,950 $101,490 0 $0 0 $0
2005-04 36,500 $438,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Dexcom Inc insiders (DXCM)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2018-10-12 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 5,000 124.86 624,300
2018-10-10 Murphy Patrick Michael (SVP, GC & Chief Compliance Officer) Sale 400 122.20 48,880
2018-10-08 Sayer Kevin R (President, CEO & Chairman) Sale 11,161 124.88 1,393,819
2018-10-08 Sayer Kevin R (President, CEO & Chairman) Option Ex 11,161 4.58 51,117
2018-10-01 Altman Steven R (Director) Sale 2,500 136.73 341,830
2018-09-28 Leach Jacob Steven (Chief Technology Officer) Sale 47,600 143.72 6,841,310
2018-09-24 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,736 140.61 244,102
2018-09-24 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 3,114 140.99 439,036
2018-09-14 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 5,000 144.86 724,320
2018-09-12 Leach Jacob Steven (SVP, Research & Development) Option Ex 15,000 5.92 88,800
2018-09-11 Blackford Quentin S. (EVP, CFO, PFO & PAO) Sale 8,440 146.75 1,238,578
2018-09-10 Leach Jacob Steven (SVP, Research & Development) Sale 4,614 143.75 663,285
2018-09-10 Murphy Patrick Michael (VP, Legal Aff & Chf Compl Ofcr) Sale 2,372 143.62 340,666
2018-09-10 Blackford Quentin S. (EVP, CFO, PFO & PAO) Sale 7,149 143.75 1,027,704
2018-09-10 Ace Heather S (SVP Human Resources) Sale 1,832 143.75 263,359
2018-09-10 Abbey Donald (EVP, Quality & Regulatory Afrs) Sale 2,303 143.75 331,067
2018-09-10 Doubleday Richard (EVP, Chief Commercial Officer) Sale 5,483 143.75 788,208
2018-09-10 Moy Jeffrey (SVP, Operations) Sale 10,330 143.62 1,483,594
2018-09-10 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 5,483 143.75 788,208
2018-09-10 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 5,587 143.75 803,159
2018-09-10 Sayer Kevin R (President, CEO & Chairman) Sale 25,495 143.44 3,657,079
2018-09-10 Sayer Kevin R (President, CEO & Chairman) Option Ex 11,161 4.58 51,117
2018-08-24 Leach Jacob Steven (SVP, Research & Development) Sale 20,577 138.32 2,846,148
2018-08-24 Leach Jacob Steven (SVP, Research & Development) Option Ex 20,577 4.55 93,728
2018-08-24 Foletta Mark G (Director) Sale 1,000 137.50 137,503
2018-08-24 Altman Steven R (Director) Sale 5,000 136.47 682,360
2018-08-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 2,584 141.11 364,638
2018-08-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 3,114 141.10 439,382
2018-08-14 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 5,000 124.56 622,805
2018-08-13 Sayer Kevin R (President, CEO & Chairman) Sale 11,161 123.43 1,377,613
2018-08-13 Sayer Kevin R (President, CEO & Chairman) Option Ex 11,161 4.58 51,117
2018-08-10 Murphy Patrick Michael (VP, Legal Aff & Chf Compl Ofcr) Sale 12,500 123.74 1,546,750
2018-08-06 Augustinos Nicholas (Director) Sale 12,300 121.47 1,494,031
2018-08-01 Moy Jeffrey (SVP, Operations) Sale 5,831 94.13 548,872
2018-07-25 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 3,114 101.94 317,428
2018-07-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 2,581 102.81 265,347
2018-07-16 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 5,000 99.92 499,590
2018-07-16 Gregg Terrance H (Executive Chairman) Sale 10,000 99.94 999,440
2018-07-09 Sayer Kevin R (President & CEO) Sale 14,219 99.86 1,419,909
2018-06-28 Moy Jeffrey (SVP, Operations) Sale 59,193 92.29 5,462,744
2018-06-25 Doubleday Richard (EVP, Chief Commercial Officer) Sale 2,581 98.58 254,432
2018-06-15 Gregg Terrance H (Executive Chairman) Sale 10,000 97.81 978,100
2018-06-12 Topol Eric (Director) Sale 20,000 100.10 2,002,000
2018-05-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 2,581 86.00 221,963
2018-05-15 Gregg Terrance H (Executive Chairman) Sale 10,000 85.90 858,970
2018-05-14 Skyler Jay S (Director) Sale 30,000 88.00 2,640,000
2018-05-14 Skyler Jay S (Director) Option Ex 30,000 4.58 137,400
2018-05-10 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Option Ex 2,855 7.63 21,783
2018-05-09 Leach Jacob Steven (SVP, Research & Development) Sale 8,745 84.77 741,331
2018-05-09 Leach Jacob Steven (SVP, Research & Development) Option Ex 8,745 8.53 74,551
2018-05-09 Sayer Kevin R (President & CEO) Sale 17,245 84.37 1,454,995
2018-05-09 Sayer Kevin R (President & CEO) Option Ex 31,464 7.63 240,070
2018-05-08 Leach Jacob Steven (SVP, Research & Development) Sale 4,423 85.05 376,184
2018-05-08 Leach Jacob Steven (SVP, Research & Development) Option Ex 1,923 3.19 6,134
2018-05-08 Skyler Jay S (Director) Sale 31,464 85.11 2,678,026
2018-05-08 Skyler Jay S (Director) Option Ex 31,464 7.63 240,070
2018-04-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 2,581 73.09 188,650
2018-04-16 Gregg Terrance H (Executive Chairman) Sale 10,000 73.04 730,410
2018-03-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 2,581 68.44 176,643
2018-03-15 Gregg Terrance H (Executive Chairman) Sale 10,000 65.51 655,120
2018-02-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,638 56.32 92,252
2018-02-15 Gregg Terrance H (Executive Chairman) Sale 10,000 55.91 559,100
2018-01-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 54.67 89,383
2018-01-16 Gregg Terrance H (Executive Chairman) Sale 10,000 56.86 568,590
2017-12-26 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 56.39 92,204
2017-12-12 Sayer Kevin R (President & CEO) Sale 6,000 58.85 353,094
2017-12-11 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 3,245 61.23 198,691
2017-11-29 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 2,900 60.12 174,339
2017-11-29 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 6,490 60.00 389,400
2017-11-27 Foletta Mark G (Director) Sale 2,500 54.95 137,385
2017-11-24 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 55.53 90,788
2017-11-20 Kahn Barbara (Director) Sale 3,000 54.58 163,728
2017-11-20 Sayer Kevin R (President & CEO) Sale 12,000 55.00 660,000
2017-11-07 Altman Steven R (Director) Buy 25,000 50.01 1,250,250
2017-11-06 Altman Steven R (Director) Buy 10,000 49.61 496,100
2017-10-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 44.82 73,274
2017-09-25 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 69.77 114,080
2017-09-25 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 69.81 101,218
2017-09-20 Sayer Kevin R (President & CEO) Sale 6,000 69.34 416,045
2017-09-11 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 3,244 72.27 234,440
2017-08-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 1,635 75.26 123,053
2017-08-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 3,987 75.26 300,045
2017-08-11 Sayer Kevin R (President & CEO) Sale 6,000 69.77 418,638
2017-08-10 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 3,244 71.18 230,920
2017-07-24 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 69.47 100,724
2017-07-12 Sayer Kevin R (President & CEO) Sale 6,000 71.86 431,171
2017-07-10 Balo Andrew K (EVP, Reg. Strategy, Clinical) Sale 3,200 71.55 228,972
2017-06-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,187 78.22 249,274
2017-06-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 78.19 113,376
2017-06-12 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 69.06 220,988
2017-06-12 Sayer Kevin R (President & CEO) Sale 6,000 69.07 414,414
2017-05-24 Gregg Terrance H (Executive Chairman) Option Ex 30,000 6.85 205,500
2017-05-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 68.29 217,289
2017-05-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 68.24 98,949
2017-05-17 Sayer Kevin R (President & CEO) Sale 8,649 68.39 591,539
2017-05-17 Sayer Kevin R (President & CEO) Option Ex 3,649 8.79 32,074
2017-05-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 71.93 230,176
2017-04-24 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 75.78 241,131
2017-04-24 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 1,450 75.89 110,040
2017-04-20 Gregg Terrance H (Executive Chairman) Sale 15,000 74.10 1,111,500
2017-04-17 Sayer Kevin R (President & CEO) Sale 10,000 75.63 756,320
2017-04-17 Sayer Kevin R (President & CEO) Option Ex 10,000 8.79 87,899
2017-04-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 78.19 250,208
2017-03-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 76.38 243,028
2017-03-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 3,987 76.25 304,004
2017-03-22 Roper Jess (SVP, CFO) Sale 2,000 75.97 151,936
2017-03-17 Sayer Kevin R (President & CEO) Sale 10,000 77.82 778,160
2017-03-17 Sayer Kevin R (President & CEO) Option Ex 10,000 8.79 87,899
2017-03-14 Leach Jacob Steven (SVP, Research & Development) Sale 3,050 77.32 235,825
2017-03-14 Kahn Barbara (Director) Sale 3,000 77.36 232,080
2017-03-13 Leach Jacob Steven (SVP, Research & Development) Sale 7,926 77.92 617,625
2017-03-13 Valdes Jorge A (CTO) Sale 14,400 77.74 1,119,513
2017-03-10 Leach Jacob Steven (SVP, Research & Development) Option Ex 7,500 7.63 57,225
2017-03-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 77.71 248,671
2017-03-09 Leach Jacob Steven (SVP, Research & Development) Sale 10,341 77.40 800,383
2017-03-09 Lister John (General Manager, EMEA) Sale 3,000 77.67 233,001
2017-03-09 Lister John (General Manager, EMEA) Option Ex 3,000 8.85 26,550
2017-03-06 Skyler Jay S (Director) Sale 31,890 78.13 2,491,565
2017-03-06 Skyler Jay S (Director) Option Ex 31,890 7.31 233,115
2017-02-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 78.42 249,529
2017-02-22 Roper Jess (SVP, CFO) Sale 2,333 78.77 183,758
2017-02-17 Sayer Kevin R (President & CEO) Sale 10,000 81.62 816,180
2017-02-17 Sayer Kevin R (President & CEO) Option Ex 10,000 8.79 87,899
2017-02-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 79.30 253,760
2017-02-10 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 727 9.80 7,124
2017-02-09 Lister John (General Manager, EMEA) Sale 3,000 79.73 239,205
2017-02-09 Lister John (General Manager, EMEA) Option Ex 3,000 8.85 26,550
2017-02-09 Valdes Jorge A (CTO) Sale 7,000 79.76 558,313
2017-02-09 Valdes Jorge A (CTO) Option Ex 7,000 9.80 68,600
2017-02-01 Valdes Jorge A (CTO) Sale 13,900 80.00 1,112,000
2017-02-01 Valdes Jorge A (CTO) Option Ex 13,900 9.80 136,220
2017-01-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 79.50 252,978
2017-01-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Sale 9,637 80.00 770,911
2017-01-23 Pacelli Steven Robert (EVP, Strategy & Corp. Dev.) Option Ex 9,637 7.79 75,072
2017-01-18 Roper Jess (SVP, CFO) Sale 3,012 85.01 256,050
2017-01-17 Sayer Kevin R (President & CEO) Sale 10,000 85.94 859,360
2017-01-17 Sayer Kevin R (President & CEO) Option Ex 10,000 8.79 87,899
2017-01-13 Lister John (General Manager, EMEA) Sale 15,000 79.36 1,190,400
2017-01-13 Lister John (General Manager, EMEA) Option Ex 15,000 8.85 132,750
2017-01-13 Valdes Jorge A (CTO) Sale 26,100 80.00 2,088,000
2017-01-13 Valdes Jorge A (CTO) Option Ex 26,100 9.08 236,909
2017-01-10 Balo Andrew K (EVP, Clinical and Regulatory) Sale 3,200 62.86 201,152
2017-01-10 Balo Andrew K (EVP, Clinical and Regulatory) Option Ex 3,200 9.80 31,360
2017-01-09 Lister John (General Manager, EMEA) Sale 3,000 63.02 189,045
2017-01-09 Lister John (General Manager, EMEA) Option Ex 3,000 8.85 26,550
2017-01-09 Valdes Jorge A (CTO) Sale 10,900 63.16 688,476
2017-01-09 Valdes Jorge A (CTO) Option Ex 10,900 6.56 71,504
2016-12-23 Doubleday Richard (EVP, Chief Commercial Officer) Sale 3,182 62.17 197,831
2016-12-14 Roper Jess (SVP, CFO) Sale 2,442 64.14 156,620
2016-12-09 Valdes Jorge A (CTO) Sale 10,000 64.81 648,080

Insider trading activities including stock purchases, stock sales, and option exercises of DXCM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Dexcom Inc (symbol DXCM, CIK number 1093557) see the Securities and Exchange Commission (SEC) website.